Sinofn Health
Sinofn Health
In the landscape of modern nutraceuticals, Coenzyme Q10 (CoQ10) remains a cornerstone supplement. However, for manufacturers and global brands, the distinction between Ubidecarenone and Ubiquinol is not merely chemical—it is a critical differentiator for product efficacy, target demographics, and market positioning.
Ubidecarenone is the oxidized form of CoQ10. It is more stable at room temperature, making it a cost-effective solution for standard shelf-stable dietary supplements. Ubiquinol, conversely, is the reduced, "active" antioxidant form. It is the form that our bodies must convert CoQ10 into for cellular energy production (ATP) and lipid-soluble antioxidant protection.
As industry experts, SINOFN recognizes that the aging population and individuals with metabolic predispositions often struggle to convert Ubidecarenone to Ubiquinol efficiently. This is where Information Gain is crucial: We don't just supply raw materials; we provide the stabilization technology required to protect the highly sensitive Ubiquinol from oxidation, ensuring that what the consumer ingests is biologically active.
The global CoQ10 market is experiencing a paradigm shift towards "Precision Nutrition." As a leading ODM, SINOFN is investing heavily in Nano-Emulsion Delivery Systems. Our roadmap includes transitioning from standard powder formulations to liquid-caplet delivery, enhancing absorption rates by up to 300% compared to traditional crystals.
Founded in 2012, SINOFN Health Co., Ltd. leverages its partnership with the Chinese Academy of Sciences to redefine contract manufacturing. We are more than an OEM; we are your R&D partner. From PKU-specialized foods to high-end CoQ10 formulations, our goal is to merge clinical precision with industrial-scale output.
Serving brands across North America, EU, and Asia.
Led by PhDs from Peking University and CAS.
ISO 22000, HACCP, and BRCGS certified.
Revenue shares dedicated to PKU accessibility.
A: We provide granular control over the oxidation state of the CoQ10 molecule. Our analytical laboratories allow us to perform stability testing under accelerated aging conditions, ensuring your product's potency claims remain accurate throughout its shelf life.
A: Yes. Our R&D department specializes in liposomal encapsulation and micronization technologies, which are essential when formulating with Ubiquinol to prevent premature degradation.
A: Our regulatory team manages documentation for FDA, EFSA, and other regional authorities. We ensure that ingredient labeling, purity specs (heavy metal/microbiological), and dosage claims align with target market requirements.
Led by Dr. Tan Shengjie and Dr. Zhang Ying, our R&D core is the engine of our innovation. With 10+ GMP production lines, we provide an end-to-end solution: from formulation optimization to pilot-scale prototyping and full-scale manufacturing.
